ADPT
Adaptive Biotechnologies Corporation$14.00-0.21 (-1.48%)Prev Close$14.21·MCap$2.19B·P/E—·Vol857.6K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
46
$59.59M
◆
Net Activity
Net Seller
$59.59M
●
Active Insiders
9
last 12 mo
Over the past 12 months, insider activity at Adaptive Biotechnologies Corporation (ADPT) has been exclusively selling, with 0 insider purchases totaling $0.00 and 46 insider sales totaling $59.59M. The most recent insider transaction was by RUBINSTEIN JULIE (officer: President and COO), who sold $798.4K worth of shares on Apr 24, 2026. Adaptive Biotechnologies Corporation operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $2.19B.
ADPT Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 24, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $13.96 | $798.4K | 390,808 |
| Apr 21, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 69,061 | $14.60 | $1.01M | 403,822 |
| Apr 16, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $14.45 | $826.3K | 416,836 |
| Apr 13, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $13.26 | $758.1K | 431,950 |
| Apr 10, 2026 | LO FRANCIS | officer: Chief People Officer | Sell | 22,564 | $15.07 | $340.0K | 271,154 |
| Apr 10, 2026 | ROBINS HARLAN S | officer: Chief Scientific Officer | Sell | 10,000 | $14.85 | $148.5K | 1,512,058 |
| Apr 8, 2026 | ROBINS CHAD M | director, officer: CEO and Chairman | Sell | 120,595 | $14.65 | $1.77M | 2,217,781 |
| Apr 8, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 69,061 | $14.34 | $990.5K | 442,864 |
| Apr 2, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 38,120 | $14.53 | $553.7K | 451,540 |
| Mar 31, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $13.14 | $751.3K | 480,876 |
| Mar 26, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $14.03 | $802.2K | 477,568 |
| Mar 23, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $13.46 | $769.6K | 490,582 |
| Mar 18, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $13.33 | $762.2K | 503,596 |
| Mar 13, 2026 | BENZENO SHARON | officer: Chief Commercial Ofc Imm Med | Sell | 63,103 | $13.17 | $831.1K | 272,751 |
| Mar 13, 2026 | BOBULSKY SUSAN | officer: Chief Commercial Officer, MRD | Sell | 41,338 | $13.17 | $544.4K | 427,775 |
| Mar 13, 2026 | GRIFFIN MICHELLE RENEE | director | Sell | 15,394 | $13.91 | $214.1K | 15,625-50% |
| Mar 13, 2026 | LO FRANCIS | officer: Chief People Officer | Sell | 30,593 | $14.08 | $430.7K | 291,374 |
| Mar 13, 2026 | PISKEL KYLE | officer: Chief Financial Officer | Sell | 18,672 | $13.17 | $245.9K | 259,840 |
| Mar 13, 2026 | ROBINS CHAD M | director, officer: CEO and Chairman | Sell | 470,167 | $13.17 | $6.19M | 2,630,713 |
| Mar 13, 2026 | ROBINS HARLAN S | officer: Chief Scientific Officer | Sell | 470,266 | $13.17 | $6.19M | 1,851,658 |
| Mar 13, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 179,703 | $13.21 | $2.37M | 520,948-26% |
| Mar 10, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 81,342 | $14.90 | $1.21M | 652,147 |
| Mar 9, 2026 | LO FRANCIS | officer: Chief People Officer | Sell | 38,074 | $15.09 | $574.5K | 321,967 |
| Mar 5, 2026 | GRIFFIN MICHELLE RENEE | director | Sell | 48,044 | $15.30 | $735.1K | 15,394-76% |
| Mar 5, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 92,823 | $16.09 | $1.49M | 590,429 |
| Feb 4, 2026 | PISKEL KYLE | Chief Financial Officer | Sell | 2,145 | $18.46 | $39.6K | 0 |
| Feb 2, 2026 | ROBINS CHAD M | CEO and Chairman | Sell | 124,998 | $18.44 | $2.30M | 0 |
| Feb 2, 2026 | ROBINS HARLAN S | Chief Scientific Officer | Sell | 42,788 | $18.68 | $799.1K | 0 |
| Jan 12, 2026 | LO FRANCIS | Chief People Officer | Sell | 79,590 | $17.73 | $1.41M | 0 |
| Jan 12, 2026 | PISKEL KYLE | Chief Financial Officer | Sell | 4,290 | $18.00 | $77.2K | 0 |
| Jan 6, 2026 | ROBINS HARLAN S | Chief Scientific Officer | Sell | 10,000 | $16.44 | $164.4K | 0 |
| Jan 5, 2026 | ROBINS CHAD M | CEO and Chairman | Sell | 124,998 | $15.59 | $1.95M | 0 |
| Jan 2, 2026 | LO FRANCIS | Chief People Officer | Sell | 3,125 | $16.08 | $50.3K | 0 |
| Dec 22, 2025 | LO FRANCIS | Chief People Officer | Sell | 4,394 | $17.50 | $76.9K | 0 |
| Dec 15, 2025 | LO FRANCIS | Chief People Officer | Sell | 113,890 | $15.57 | $1.77M | 0 |
| Dec 10, 2025 | HERSHBERG ROBERT | Director | Sell | 22,968 | $16.00 | $367.5K | 0 |
| Dec 4, 2025 | BENZENO SHARON | Chief Commercial Ofc Imm Med | Sell | 12,604 | $16.85 | $212.4K | 0 |
| Dec 3, 2025 | ROBINS HARLAN S | Chief Scientific Officer | Sell | 37,212 | $18.07 | $672.5K | 0 |
| Nov 28, 2025 | PISKEL KYLE | Chief Financial Officer | Sell | 162,820 | $19.50 | $3.17M | 0 |
| Nov 26, 2025 | ROBINS CHAD M | CEO and Chairman | Sell | 160,734 | $19.10 | $3.07M | 0 |
| Nov 20, 2025 | BENZENO SHARON | Chief Commercial Ofc Imm Med | Sell | 606,402 | $16.73 | $10.14M | 0 |
| Nov 17, 2025 | PISKEL KYLE | Chief Financial Officer | Sell | 238 | $14.05 | $3.3K | 0 |
| Nov 10, 2025 | ROBINS CHAD M | CEO and Chairman | Sell | 89,265 | $14.73 | $1.32M | 0 |
| Nov 10, 2025 | ROBINS HARLAN S | Chief Scientific Officer | Sell | 10,000 | $14.82 | $148.2K | 0 |
| May 15, 2025 | PISKEL KYLE | Chief Financial Officer | Sell | 1,929 | $8.89 | $17.1K | 0 |
| May 1, 2025 | ROBINS HARLAN S | Chief Scientific Officer | Sell | 68,412 | $7.35 | $502.8K | 0 |
| Mar 24, 2025 | ROBINS HARLAN S | Chief Scientific Officer | Sell | 1,698 | $9.00 | $15.3K | 0 |
| Mar 13, 2025 | GRIFFIN MICHELLE RENEE | Director | Sell | 36,291 | $7.19 | $260.9K | 0 |
| Mar 12, 2025 | HERSHBERG ROBERT | Director | Sell | 53,000 | $7.59 | $402.3K | 0 |
| Mar 10, 2025 | NEUPERT PETER M | Director | Sell | 10,000 | $7.05 | $70.5K | 0 |
Showing 1–50 of 170
1 / 4
ADPT Insider Buying Activity
The following table shows recent insider purchases of Adaptive Biotechnologies Corporation (ADPT) stock reported via SEC Form 4 filings.
No insider buying activity found for ADPT in the last 12 months.
ADPT Insider Selling Activity
The following table shows recent insider sales of Adaptive Biotechnologies Corporation (ADPT) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 24, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $13.96 | $798.4K | 390,808 |
| Apr 21, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 69,061 | $14.60 | $1.01M | 403,822 |
| Apr 16, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $14.45 | $826.3K | 416,836 |
| Apr 13, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $13.26 | $758.1K | 431,950 |
| Apr 10, 2026 | LO FRANCIS | officer: Chief People Officer | Sell | 22,564 | $15.07 | $340.0K | 271,154 |
| Apr 10, 2026 | ROBINS HARLAN S | officer: Chief Scientific Officer | Sell | 10,000 | $14.85 | $148.5K | 1,512,058 |
| Apr 8, 2026 | ROBINS CHAD M | director, officer: CEO and Chairman | Sell | 120,595 | $14.65 | $1.77M | 2,217,781 |
| Apr 8, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 69,061 | $14.34 | $990.5K | 442,864 |
| Apr 2, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 38,120 | $14.53 | $553.7K | 451,540 |
| Mar 31, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $13.14 | $751.3K | 480,876 |
| Mar 26, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $14.03 | $802.2K | 477,568 |
| Mar 23, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $13.46 | $769.6K | 490,582 |
| Mar 18, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $13.33 | $762.2K | 503,596 |
| Mar 13, 2026 | BENZENO SHARON | officer: Chief Commercial Ofc Imm Med | Sell | 63,103 | $13.17 | $831.1K | 272,751 |
| Mar 13, 2026 | BOBULSKY SUSAN | officer: Chief Commercial Officer, MRD | Sell | 41,338 | $13.17 | $544.4K | 427,775 |
| Mar 13, 2026 | GRIFFIN MICHELLE RENEE | director | Sell | 15,394 | $13.91 | $214.1K | 15,625-50% |
| Mar 13, 2026 | LO FRANCIS | officer: Chief People Officer | Sell | 30,593 | $14.08 | $430.7K | 291,374 |
| Mar 13, 2026 | PISKEL KYLE | officer: Chief Financial Officer | Sell | 18,672 | $13.17 | $245.9K | 259,840 |
| Mar 13, 2026 | ROBINS CHAD M | director, officer: CEO and Chairman | Sell | 470,167 | $13.17 | $6.19M | 2,630,713 |
| Mar 13, 2026 | ROBINS HARLAN S | officer: Chief Scientific Officer | Sell | 470,266 | $13.17 | $6.19M | 1,851,658 |
| Mar 13, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 179,703 | $13.21 | $2.37M | 520,948-26% |
| Mar 10, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 81,342 | $14.90 | $1.21M | 652,147 |
| Mar 9, 2026 | LO FRANCIS | officer: Chief People Officer | Sell | 38,074 | $15.09 | $574.5K | 321,967 |
| Mar 5, 2026 | GRIFFIN MICHELLE RENEE | director | Sell | 48,044 | $15.30 | $735.1K | 15,394-76% |
| Mar 5, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 92,823 | $16.09 | $1.49M | 590,429 |
| Feb 4, 2026 | PISKEL KYLE | Chief Financial Officer | Sell | 2,145 | $18.46 | $39.6K | 0 |
| Feb 2, 2026 | ROBINS CHAD M | CEO and Chairman | Sell | 124,998 | $18.44 | $2.30M | 0 |
| Feb 2, 2026 | ROBINS HARLAN S | Chief Scientific Officer | Sell | 42,788 | $18.68 | $799.1K | 0 |
| Jan 12, 2026 | LO FRANCIS | Chief People Officer | Sell | 79,590 | $17.73 | $1.41M | 0 |
| Jan 12, 2026 | PISKEL KYLE | Chief Financial Officer | Sell | 4,290 | $18.00 | $77.2K | 0 |
| Jan 6, 2026 | ROBINS HARLAN S | Chief Scientific Officer | Sell | 10,000 | $16.44 | $164.4K | 0 |
| Jan 5, 2026 | ROBINS CHAD M | CEO and Chairman | Sell | 124,998 | $15.59 | $1.95M | 0 |
| Jan 2, 2026 | LO FRANCIS | Chief People Officer | Sell | 3,125 | $16.08 | $50.3K | 0 |
| Dec 22, 2025 | LO FRANCIS | Chief People Officer | Sell | 4,394 | $17.50 | $76.9K | 0 |
| Dec 15, 2025 | LO FRANCIS | Chief People Officer | Sell | 113,890 | $15.57 | $1.77M | 0 |
| Dec 10, 2025 | HERSHBERG ROBERT | Director | Sell | 22,968 | $16.00 | $367.5K | 0 |
| Dec 4, 2025 | BENZENO SHARON | Chief Commercial Ofc Imm Med | Sell | 12,604 | $16.85 | $212.4K | 0 |
| Dec 3, 2025 | ROBINS HARLAN S | Chief Scientific Officer | Sell | 37,212 | $18.07 | $672.5K | 0 |
| Nov 28, 2025 | PISKEL KYLE | Chief Financial Officer | Sell | 162,820 | $19.50 | $3.17M | 0 |
| Nov 26, 2025 | ROBINS CHAD M | CEO and Chairman | Sell | 160,734 | $19.10 | $3.07M | 0 |
| Nov 20, 2025 | BENZENO SHARON | Chief Commercial Ofc Imm Med | Sell | 606,402 | $16.73 | $10.14M | 0 |
| Nov 17, 2025 | PISKEL KYLE | Chief Financial Officer | Sell | 238 | $14.05 | $3.3K | 0 |
| Nov 10, 2025 | ROBINS CHAD M | CEO and Chairman | Sell | 89,265 | $14.73 | $1.32M | 0 |
| Nov 10, 2025 | ROBINS HARLAN S | Chief Scientific Officer | Sell | 10,000 | $14.82 | $148.2K | 0 |
| May 15, 2025 | PISKEL KYLE | Chief Financial Officer | Sell | 1,929 | $8.89 | $17.1K | 0 |
| May 1, 2025 | ROBINS HARLAN S | Chief Scientific Officer | Sell | 68,412 | $7.35 | $502.8K | 0 |
| Mar 24, 2025 | ROBINS HARLAN S | Chief Scientific Officer | Sell | 1,698 | $9.00 | $15.3K | 0 |
| Mar 13, 2025 | GRIFFIN MICHELLE RENEE | Director | Sell | 36,291 | $7.19 | $260.9K | 0 |
| Mar 12, 2025 | HERSHBERG ROBERT | Director | Sell | 53,000 | $7.59 | $402.3K | 0 |
| Mar 10, 2025 | NEUPERT PETER M | Director | Sell | 10,000 | $7.05 | $70.5K | 0 |
ADPT Insiders
Similar Stocks to ADPT
VRTX
Vertex Pharmaceuticals Incorporated
$429.47+0.81%
$111.71B
REGN
Regeneron Pharmaceuticals, Inc.
$734.06-1.39%
$77.87B
ALNY
Alnylam Pharmaceuticals, Inc.
$303.44-1.64%
$41.24B
INSM
Insmed Incorporated
$135.11-0.64%
$30.79B
RVMD
Revolution Medicines, Inc.
$144.62+9.92%
$29.51B
UTHR
United Therapeutics Corporation
$566.69+0.03%
$25.13B
MRNA
Moderna, Inc.
$47.16-3.17%
$21.42B
RPRX
Royalty Pharma plc
$49.40-0.50%
$21.20B